20250423-盈立证券-维亚生物-01873.HK-Deeply_Engaged_in_AI-driven_drug_R_D_revolution,_Viva_Starts_a_New_Era_of_Globalized_CRDMO_Businesses_43页_2mb
报告摘要
Viva Biotech (1873.HK) Summary
Core Investment Thesis
Viva Biotech is a global leader in Structure-Based Drug Discovery (SBDD), with a strong focus on AI-driven drug R&D and CDMO services. The company has built an integrated drug R&D and manufacturing platform, combining its advanced SBDD capabilities with CDMO services through the acquisition of Langhua Pharma in 2020. It also employs a unique "service + investment" business model (EFS), allowing it to generate both short-term service revenue and long-term investment returns.
Key Highlights
- Market Position: Viva is the leading SBDD provider in China and a global leader in protein structure research.
- Integrated Platform: Combines CRO and CDMO services, enabling one-stop solutions for innovative drug development.
- AI Integration: Utilizes AI to enhance drug discovery and manufacturing efficiency, with a proprietary AI platform expected to launch in 2025.
- Strategic Investors: Secured USD 225 million in 2023 from Temasek, Highlight Capital, True Light, and Dubai Investment Corporation.
- Growth Prospects: Strong revenue growth expected from 2025 to 2028, with consistent improvements in gross margin and net profit margins.
- Target Price: 3.5 HKD, indicating a potential upside of 133% from the current price of 1.5 HKD.
Financial Overview
| Metric | 2023A | 2024A | 2025E | 2026E | 2027E | 2028E |
|---|---|---|---|---|---|---|
| Revenue (CNY million) | 2156 | 1987 | 2264 | 2581 | 2943 | 3355 |
| Revenue YOY | -9.4% | -7.8% | 13.9% | 14.0% | 14.0% | 14.0% |
| Gross Profit (CNY million) | 738 | 687 | 803 | 940 | 1099 | 1284 |
| Gross Profit YOY | -9.6% | -6.9% | 16.9% | 17.1% | 16.9% | 16.8% |
| Gross Margin | 34.3% | 34.6% | 35.5% | 36.4% | 37.3% | 38.3% |
| Net Profit (CNY million) | -100 | 222 | 275 | 330 | 394 | 471 |
| Net Profit Margin | -4.6% | 11.2% | 12.1% | 12.8% | 13.4% | 14.0% |
| Adjusted Net Profit (CNY million) | 209 | 315 | 345 | 400 | 464 | 541 |
| Diluted EPS (CNY) | 0.09 | 0.09 | 0.15 | 0.17 | 0.20 | 0.23 |
Competitive Advantages
- SBDD Leadership: Has the largest research platform for protein structures globally.
- CDMO Expansion: Acquired Langhua Pharma to offer full CMC and CDMO services, serving top pharmaceutical companies.
- AI-Driven Innovation: Developed proprietary AI platforms for drug design and discovery, with a focus on new targets, MOA, and modalities.
- High-Quality Services: Offers a wide range of services including X-ray crystallography, Cryo-EM, ASMS, and AIDD/CADD.
- Strong Client Base: Has 1,568 CRO clients, with top 10 clients contributing 24.4% of revenue. Over 87% of revenue comes from overseas clients.
- Cost Optimization: Reduced R&D staff by 1,121 in 2024, while maintaining revenue per employee over CNY 610,000.
Strategic Developments
- M&A History: Acquired Langhua Pharma (2020) and SYNthesis Med Chem (2021) to strengthen its CRO and CDMO capabilities.
- Global Expansion: Established a Boston branch in 2024, marking progress in international market development.
- Internal Reorganization: Plans to spin off CRO business for China A-share listing, with CDMO operations managed by other subsidiaries.
Valuation & Market Comparison
| Company | Close (HKD) | YTD (%) | Market Cap (HKDbn) | 2024 Revenue (HKDbn) | 2024 PE | P/B |
|---|---|---|---|---|---|---|
| Viva Biotech | 1.5 | 74.42% | 3.20 | 1.99 | 17.70 | 0.78 |
| Biocytogen | 11.62 | 36.71% | 4.64 | 0.98 | 128.13 | 5.17 |
| Frontage Labs | 1.2 | -32.58% | 2.44 | 1.91 | 397.85 | 0.57 |
| XtalPi | 4.88 | -18.39% | 19.62 | 0.25 | -11.98 | 4.60 |
| Harbour BioMed | 7.85 | 322.04% | 6.63 | 0.26 | 307.39 | 6.87 |
| PharmaBlock | 31.38 | -6.61% | 6.27 | 1.62 | 31.76 | 2.26 |
| HitGen | 14.43 | 17.13% | 5.78 | 0.43 | 141.99 | 4.19 |
Conclusion
Viva Biotech is well-positioned to benefit from the global shift towards AI-driven drug discovery and the expansion of the CRO and CDMO markets. Its integrated platform, strong technological foundation, and strategic investments make it a compelling buy with a target price of 3.5 HKD, offering a significant upside potential from the current valuation. The company's focus on innovation and efficiency, combined with a growing client base and strong financial performance, supports its long-term growth prospects.
试读结束，高清完整版pdf/doc/ppt,请点下载
